{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:28:49Z","timestamp":1770971329050,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0008823","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000}}],"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Globally, early initiation of antiretroviral therapy for HIV led to a reduction in the estimated mortality from cryptococcal meningitis (CCM) from 624,700 in 2009 to 181,100 in 2014. However, CCM remains one of the leading causes of mortality among HIV infected patients especially in sub-Saharan Africa where 75% of the deaths occur. Most of the studies evaluating mortality have reported short-term mortality (at or before 10 weeks of therapy). We determined mortality and associated factors among patients treated for CCM in the CryptoDex trial (ISRCTN59144167) in Uganda, and the effect of dexamethasone adjunctive therapy on mortality at two years. We conducted a retrospective cohort study between May 2017 and July 2017 to determine the long term survival (up to 2 years post-randomization) of all patients who had been enrolled into the CryptoDex trial in Uganda. The CryptoDex trial recruited between April 2013 and February 2015. We estimated mortality rates and determined factors affecting mortality at two years using Cox regression. The study followed up 211 participants, 127 (60.2%) of whom were male. Sixteen participants (7.58%) were diagnosed with HIV at the same admission when CCM was diagnosed. By two years following randomization 127 (60%) participants had died, a mortality rate of 67 deaths per 100 person-years. Mortality was associated with Glasgow coma score (GCS) below 15 (adjusted Hazard ratio (aHR) 1.77, 95% CI: 1.02\u20132.44), p = 0.040; weight (aHR 0.97, per 1 Kg increase; 95% CI: 0.94\u20130.99), p = 0.003; and presence of convulsions (aHR 2.31, 95% CI: 1.32\u20134.04), p = 0.004, while dexamethasone use and fungal burden had no effect. Long-term mortality in CCM patients remains high even among patients receiving recommended therapy. Strategies to improve long-term survival in CCM patients are urgently needed, especially targeting those with reduced GCS, low weight, and convulsions.<\/jats:p>","DOI":"10.1371\/journal.pntd.0008823","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T19:10:24Z","timestamp":1606763424000},"page":"e0008823","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Determinants of two-year mortality among HIV positive patients with Cryptococcal meningitis initiating standard antifungal treatment with or without adjunctive dexamethasone in Uganda"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-4037","authenticated-orcid":true,"given":"Jonathan","family":"Kitonsa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8527-6222","authenticated-orcid":true,"given":"Rebecca","family":"Nsubuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0414-1818","authenticated-orcid":true,"given":"Yunia","family":"Mayanja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9442-1719","authenticated-orcid":true,"given":"Julius","family":"Kiwanuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0219-8538","authenticated-orcid":true,"given":"Yofesi","family":"Nikweri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7158-6120","authenticated-orcid":true,"given":"Martin","family":"Onyango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5771-5515","authenticated-orcid":true,"given":"Zacchaeus","family":"Anywaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abu-Baker","family":"Ggayi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freddie Mukasa","family":"Kibengo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9706-2977","authenticated-orcid":true,"given":"Pontiano","family":"Kaleebu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7843-6280","authenticated-orcid":true,"given":"Jeremy","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"issue":"4","key":"pntd.0008823.ref001","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(13)70692-3","article-title":"Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial","volume":"14","author":"B Grinsztejn","year":"2014","journal-title":"The Lancet Infectious Diseases"},{"issue":"4","key":"pntd.0008823.ref002","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"BJ Park","year":"2009","journal-title":"AIDS (London, England)."},{"issue":"8","key":"pntd.0008823.ref003","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"R Rajasingham","year":"2017","journal-title":"The Lancet Infectious Diseases"},{"key":"pntd.0008823.ref004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2334-10-67","article-title":"Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases","volume":"10","author":"JN Jarvis","year":"2010","journal-title":"BMC Infectious Diseases"},{"issue":"1","key":"pntd.0008823.ref005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","article-title":"Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome.","volume":"337","author":"CM van der Horst","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pntd.0008823.ref006","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jinf.2011.10.014","article-title":"Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis","volume":"64","author":"CK Muzoora","year":"2012","journal-title":"Journal of Infection"},{"issue":"4","key":"pntd.0008823.ref007","article-title":"Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings","author":"D Sloan","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"pntd.0008823.ref008","first-page":"1363","article-title":"A Phase II Randomised Controlled Trial Adding Oral Flucytosine to High Dose Fluconazole, with Short-course Amphotericin B, for Cryptococcal Meningitis","volume":"26","author":"A Jackson","year":"2012"},{"issue":"1","key":"pntd.0008823.ref009","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/cid\/cir745","article-title":"Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis","volume":"54","author":"A Loyse","year":"2012","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"pntd.0008823.ref010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/515110","article-title":"A Comparison of Itraconazole Versus Fluconazole as Maintenance Therapy for AIDS-Associated Cryptococcal Meningitis","volume":"28","author":"MS Saag","year":"1999","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"pntd.0008823.ref011","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1086\/587667","article-title":"Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral Therapy","volume":"46","author":"A Kambugu","year":"2008","journal-title":"Clinical Infectious Diseases"},{"key":"pntd.0008823.ref012","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/CLEP.S38850","volume":"6","author":"DJ Sloan","year":"2014","journal-title":"Clinical Epidemiology"},{"key":"pntd.0008823.ref013","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s40588-016-0035-5","article-title":"HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings","volume":"3","author":"MW Tenforde","year":"2016","journal-title":"Curr Clin Microbiol Rep."},{"issue":"14","key":"pntd.0008823.ref014","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination Antifungal Therapy for Cryptococcal Meningitis.","volume":"368","author":"JN Day","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"pntd.0008823.ref015","doi-asserted-by":"crossref","first-page":"e51291","DOI":"10.1371\/journal.pone.0051291","article-title":"Long Term 5-Year Survival of Persons with Cryptococcal Meningitis or Asymptomatic Subclinical Antigenemia in Uganda","volume":"7","author":"EK Butler","year":"2012","journal-title":"PLOS ONE"},{"key":"pntd.0008823.ref016","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/1745-6215-15-441","article-title":"CryptoDex: a randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial","volume":"15","author":"J Day","year":"2014","journal-title":"Trials"},{"issue":"4","key":"pntd.0008823.ref017","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7326\/0003-4819-155-4-201108160-00358","article-title":"Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: A cohort analysis from uganda","volume":"155","author":"EJ Mills","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"pntd.0008823.ref018","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMoa1509024","article-title":"Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis.","volume":"374","author":"J Beardsley","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"pntd.0008823.ref019","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/cid\/cit794","article-title":"Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes.","volume":"58","author":"JN Jarvis","year":"2014","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America"},{"issue":"7","key":"pntd.0008823.ref020","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1473-3099(16)00074-8","article-title":"Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study","volume":"16","author":"J Rhein","year":"2016","journal-title":"The Lancet Infectious Diseases"},{"issue":"26","key":"pntd.0008823.ref021","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","article-title":"Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis","volume":"370","author":"DR Boulware","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"pntd.0008823.ref022","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1473-3099(16)00074-8","article-title":"Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study","volume":"16","author":"J Rhein","year":"2016","journal-title":"The Lancet Infectious diseases"},{"issue":"5","key":"pntd.0008823.ref023","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/QAI.0b013e31811ed32c","article-title":"Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients","volume":"45","author":"R Micol","year":"2007","journal-title":"Journal of acquired immune deficiency syndromes (1999)."},{"issue":"7","key":"pntd.0008823.ref024","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00002030-200205030-00009","article-title":"Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults","volume":"16","author":"N French","year":"2002","journal-title":"AIDS (London, England)."},{"key":"pntd.0008823.ref025","first-page":"CD005647","article-title":"Treatment for HIV-associated cryptococcal meningitis","volume":"7","author":"MW Tenforde","year":"2018","journal-title":"The Cochrane database of systematic reviews"},{"issue":"9","key":"pntd.0008823.ref026","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/cid\/ciy725","article-title":"Do Intracerebral Cytokine Responses Explain the Harmful Effects of Dexamethasone in Human Immunodeficiency Virus-associated Cryptococcal Meningitis?","volume":"68","author":"J Beardsley","year":"2019","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America."},{"issue":"3","key":"pntd.0008823.ref027","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/cid\/ciz454","article-title":"One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi.","volume":"70","author":"C Kanyama","year":"2020","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"4","key":"pntd.0008823.ref028","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/jinf.2001.0916","article-title":"A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B","volume":"43","author":"P Pitisuttithum","year":"2001","journal-title":"The Journal of infection"},{"issue":"11","key":"pntd.0008823.ref029","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/QAD.0b013e32834884e6","article-title":"Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection","volume":"25","author":"R Scherzer","year":"2011","journal-title":"AIDS (London, England)."},{"issue":"11","key":"pntd.0008823.ref030","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz478","article-title":"Seizures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Predictors and Outcomes","volume":"6","author":"KA Pastick","year":"2019","journal-title":"Open forum infectious diseases"},{"issue":"1","key":"pntd.0008823.ref031","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12883-014-0208-x","article-title":"Predictors and long-term outcome of seizures in human immuno-deficiency virus (HIV)-negative cryptococcal meningitis","volume":"14","author":"C-W Hung","year":"2014","journal-title":"BMC neurology"},{"issue":"5","key":"pntd.0008823.ref032","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s11136-004-4715-x","article-title":"Health-related quality of life of patients with HIV: Impact of sociodemographic, clinical and psychosocial factors","volume":"14","author":"IR Perez","year":"2005","journal-title":"Quality of Life Research"},{"issue":"7","key":"pntd.0008823.ref033","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0277-9536(03)00314-9","article-title":"Social support and quality of life over time among adults living with HIV in the HAART era.","volume":"58","author":"R Burgoyne","year":"2004","journal-title":"Social Science & Medicine"},{"issue":"4","key":"pntd.0008823.ref034","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/jof3040067","article-title":"HIV-Associated Cryptococcal Disease in Resource-Limited Settings: A Case for \u201cPrevention Is Better Than Cure\u201d?","volume":"3","author":"RO Oladele","year":"2017","journal-title":"Journal of Fungi"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0008823","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0008823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T20:10:26Z","timestamp":1607631026000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0008823"}},"subtitle":[],"editor":[{"given":"Angel","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0008823","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0008823","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]}}}